Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.”

A startup developing a one-time treatment that is intended to rewind the clock on dying cells announced a major influx of funding. Life Biosciences, a

A San Diego biotech looking to double up on the power of antibody-drug conjugates with fewer toxicities has patched together a $137 million Series B

The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.

Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill